{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:17:03Z","timestamp":1791411423547,"version":"4.3.3"},"reference-count":137,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2016,4,10]]},"abstract":"<jats:p>Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma previously considered to have a poor prognosis. Large gains were made in the first decade of the new century when clinical trials established the importance of high-dose therapy and autologous stem-cell rescue and high-dose cytarabine in younger patients and the benefits of maintenance rituximab and bendamustine in older patients. In particular, greater depth of understanding of the molecular pathophysiology of MCL has resulted in an explosion of specifically targeted new efficacious agents. In particular, agents recently approved by the Food and Drug Administration include the proteasome inhibitor bortezomib, immunomodulator lenalidomide, and Bruton\u2019s tyrosine kinase inhibitor ibrutinib. We review recent advances in the understanding of MCL biology and outline our recommended approach to therapy, including choice of chemoimmunotherapy, the role of stem-cell transplantation, and mechanism-based targeted therapies, on the basis of a synthesis of the data from published clinical trials.<\/jats:p>","DOI":"10.1200\/jco.2015.63.5904","type":"journal-article","created":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T23:24:41Z","timestamp":1452554681000},"page":"1256-1269","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":246,"title":["Mantle Cell Lymphoma"],"prefix":"10.1200","volume":"34","author":[{"given":"Chan Yoon","family":"Cheah","sequence":"first","affiliation":[{"name":"Chan Yoon Cheah, Sir Charles Gairdner Hospital and PathWest Laboratory Medicine WA, Nedlands; Chan Yoon Cheah, University of Western Australia, Crawley, Western Australia; John F. Seymour, Peter MacCallum Cancer Centre, East Melbourne; John F. Seymour, University of Melbourne, Parkville, Victoria, Australia; and Chan Yoon Cheah and Michael L. Wang, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[{"name":"Chan Yoon Cheah, Sir Charles Gairdner Hospital and PathWest Laboratory Medicine WA, Nedlands; Chan Yoon Cheah, University of Western Australia, Crawley, Western Australia; John F. Seymour, Peter MacCallum Cancer Centre, East Melbourne; John F. Seymour, University of Melbourne, Parkville, Victoria, Australia; and Chan Yoon Cheah and Michael L. Wang, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Wang","sequence":"additional","affiliation":[{"name":"Chan Yoon Cheah, Sir Charles Gairdner Hospital and PathWest Laboratory Medicine WA, Nedlands; Chan Yoon Cheah, University of Western Australia, Crawley, Western Australia; John F. Seymour, Peter MacCallum Cancer Centre, East Melbourne; John F. Seymour, University of Melbourne, Parkville, Victoria, Australia; and Chan Yoon Cheah and Michael L. Wang, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","unstructured":"SHCE Swerdlow, E Campo, N Harris, etal: WHO Classification of Tumours of the Haematopoeitic and Lymphoid Tissues (ed 4). Lyon, France, International Agency for Research on Cancer, 2008"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23608"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.10.1470"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(00)00255-2"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61272"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90540-1"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.08.012"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nature08684"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.141"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12854"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-1615"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.010264"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-438937"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-569566"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00028-X"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.2977.2977"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-517177"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1314608110"},{"key":"B20","unstructured":"Balasubramanian S, Schaffer M, Deraedt W, et al: Mutational analysis of patients with primary resistance to single-agent ibrutinib in relapsed or refractory mantle cell lymphoma (MCL). Presented at the ASH Annual Meeting and Exposition, San Francisco, CA, December 6-9, 2014"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0098"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-391474"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2011.09.006"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-185827"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-424630"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3376"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2067"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1995.tb00615.x"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-5125"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.2137"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.071340"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1753"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0015"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-559930"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11096"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt139"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv074"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"B41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/hon.2154","volume":"33","author":"Hoster E","year":"2015","journal-title":"Hematol Oncol"},{"key":"B42","unstructured":"Delfau-Larue M-H, Klapper W, Berger F, et al: CDKN2A and TP53 deletions predict adverse outcome in younger mantle cell lymphoma patients, independent of treatment and MIPI. Presented at the ASH Annual Meeting and Exposition, Orlando, FL, December 5-8, 2015"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3419"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.6121"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg414"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.711828"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.04.013"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200920"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-370320"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"B53","first-page":"131","volume":"33","author":"Le Gouill S","year":"2015","journal-title":"Hematol Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-541953"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt070"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08958.x"},{"key":"B57","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2013.088377","volume":"98","author":"Arranz R","year":"2013","journal-title":"Haematologica"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09174.x"},{"key":"B59","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","volume":"150","author":"Romaguera JE","year":"2010","journal-title":"Br J Haematol"},{"key":"B59a","author":"Chihara D","journal-title":"Br J Haematol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-369629"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-006-0193-2"},{"key":"B62","first-page":"132","volume":"33","author":"Chen R","year":"2015","journal-title":"Hematol Oncol"},{"key":"B63","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3109\/10428194.2011.575492","volume":"52","author":"Herbert KE","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.9842"},{"key":"B65","first-page":"130","volume":"33","author":"Visco C","year":"2015","journal-title":"Hematol Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.2444"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412096"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.332"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3985.3985"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.149.149"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1028055"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701618268"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1080\/10428190801993470"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23880"},{"key":"B78","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner R","year":"2006","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu097"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70128-2"},{"key":"B82","doi-asserted-by":"crossref","unstructured":"Davids MS, Seymour JF, Gerecitano JF, et al: Phase I study of ABT-199 (GDC-0199) in patients with relapsed\/refractory (R\/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. J Clin Oncol 32, 2014 (suppl; abstr 8522)","DOI":"10.1200\/jco.2014.32.15_suppl.8522"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.1398"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt366"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2835"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7977"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.053173"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12780"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-537555"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn656"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr450"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.1142"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.148.148"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08315.x"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-523845"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-597914"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.1714.1714"},{"key":"B101","first-page":"131","volume":"33","author":"Albertsson-Lindblad A","year":"2015","journal-title":"Hematol Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08820.x"},{"key":"B103","first-page":"1433","volume":"90","author":"Hipp S","year":"2005","journal-title":"Haematologica"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.466"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23580"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.09.027"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1177\/2040620714532124"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-0750"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.106"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07626.x"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq626"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70200-0"},{"key":"B113","doi-asserted-by":"crossref","unstructured":"Ruan J, Martin P, Shah BD, et al: Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med 373:1835-1844, 2015","DOI":"10.1056\/NEJMoa1505237"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386417"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"B117","author":"Wang MK","journal-title":"Lancet Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv111"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70311-0"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12769"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.9585"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00546.x"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01360.x"},{"key":"B124","doi-asserted-by":"crossref","unstructured":"Evens AM, Vose JM, Harb W, et al: A phase II multicenter study of the histone deacetylase inhibitor (HDACi) abexinostat (PCI-24781) in relapsed\/refractory follicular lymphoma (FL) and mantle cell lymphoma (MCL). Blood 120, 2012 (abstr 55)","DOI":"10.1182\/blood.V120.21.55.55"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23537"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05630.x"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386763"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-275305"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388298"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7898"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3048"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181ac6138"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.84.84"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0695"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70062-6"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2015.63.5904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T15:16:26Z","timestamp":1718291786000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2015.63.5904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,10]]},"references-count":137,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,4,10]]}},"alternative-id":["10.1200\/JCO.2015.63.5904"],"URL":"https:\/\/doi.org\/10.1200\/jco.2015.63.5904","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,10]]},"assertion":[{"value":"2016-01-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}